anti-TEM8 CAR T-cell therapy (University of Florida/Baylor College of Medicine/George-Speyer-Haus Chem Inst/NCI)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-TEM8 CAR T-cell therapy (University of Florida/Baylor College of Medicine/George-Speyer-Haus Chem Inst/NCI)
Drug Alias Nametumor endothelial marker 8 (TEM8)-specific chimeric antigen receptor T cell (University of Florida/Baylor College of Medicine/George-Speyer-Haus Chem Inst/NCI)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnthrax toxin receptor 1 modulators
TargetsAnthrax toxin receptor 1
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGeorg-Speyer-Haus Chem InstNational Cancer InstituteUniversity Of Florida +[4] 
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A